Pfizer Inc (PFE)
28.02
-0.16
(-0.59%)
USD |
NYSE |
May 10, 16:00
28.00
-0.02
(-0.05%)
After-Hours: 19:43
Pfizer Enterprise Value: 216.74B for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 216.74B |
| May 08, 2024 | 217.25B |
| May 07, 2024 | 214.42B |
| May 06, 2024 | 216.63B |
| May 03, 2024 | 214.64B |
| May 02, 2024 | 214.03B |
| May 01, 2024 | 211.08B |
| April 30, 2024 | 202.24B |
| April 29, 2024 | 202.36B |
| April 26, 2024 | 201.00B |
| April 25, 2024 | 200.20B |
| April 24, 2024 | 205.93B |
| April 23, 2024 | 206.21B |
| April 22, 2024 | 205.87B |
| April 19, 2024 | 204.40B |
| April 18, 2024 | 200.94B |
| April 17, 2024 | 201.11B |
| April 16, 2024 | 202.64B |
| April 15, 2024 | 203.89B |
| April 12, 2024 | 203.60B |
| April 11, 2024 | 206.32B |
| April 10, 2024 | 206.21B |
| April 09, 2024 | 208.82B |
| April 08, 2024 | 207.68B |
| April 05, 2024 | 208.14B |
| Date | Value |
|---|---|
| April 04, 2024 | 208.08B |
| April 03, 2024 | 211.31B |
| April 02, 2024 | 213.18B |
| April 01, 2024 | 214.14B |
| March 31, 2024 | 214.31B |
| March 28, 2024 | 215.56B |
| March 27, 2024 | 215.73B |
| March 26, 2024 | 214.66B |
| March 25, 2024 | 213.75B |
| March 22, 2024 | 213.36B |
| March 21, 2024 | 215.05B |
| March 20, 2024 | 215.28B |
| March 19, 2024 | 214.89B |
| March 18, 2024 | 215.39B |
| March 15, 2024 | 216.64B |
| March 14, 2024 | 217.72B |
| March 13, 2024 | 218.23B |
| March 12, 2024 | 217.04B |
| March 11, 2024 | 219.08B |
| March 08, 2024 | 212.56B |
| March 07, 2024 | 210.13B |
| March 06, 2024 | 212.39B |
| March 05, 2024 | 206.11B |
| March 04, 2024 | 205.03B |
| March 01, 2024 | 209.00B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
167.23B
Minimum
Dec 14 2023
352.78B
Maximum
Dec 16 2021
247.56B
Average
243.82B
Median
Enterprise Value Benchmarks
| Amgen Inc | 222.12B |
| Johnson & Johnson | 368.05B |
| Eli Lilly and Co | 757.00B |
| Viking Therapeutics Inc | 7.882B |
| Moderna Inc | 38.50B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.115B |
| Revenue (Quarterly) | 14.88B |
| Total Expenses (Quarterly) | 10.68B |
| EPS Diluted (Quarterly) | 0.55 |
| Gross Profit Margin (Quarterly) | 77.29% |
| Profit Margin (Quarterly) | 20.94% |
| Earnings Yield | -0.21% |
| Operating Earnings Yield | 0.75% |
| Normalized Earnings Yield | 2.137 |